Q2057Afamitresgene autoleucel
Published CMS Medicare Part B payment-limit context for Q2057, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.
CMS payment limit
$813,967.375
per THERAPEUTIC DOSE · Medicare Part B
Up 5.6%from $770,620.00 in 2026-Q2
- Current quarter
- Billing unit
Payment limit over time
$820,036.0075$764,551.3675
2024-Q4: Not published; 2025-Q1: Not published; 2025-Q2: Not published; 2025-Q3: $770,620.00; 2025-Q4: $770,620.00; 2026-Q1: $770,620.00; 2026-Q2: $770,620.00; 2026-Q3: $813,967.375
No current FDA shortage matchThe latest completed FDA data has no affected record matching the Afamitresgene Autoleucel ingredient family (FDA data as of August 20, 2026).
Tecelra
Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.
Presentation updates
Put another code on your radar.
Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.